Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.44 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL96650 | 0.83 | ENPP2 (0.52) | ENPP2PTGS2KCNJ1KCNH2CA2 | |
| SCHEMBL13231429 | 0.80 | ENPP2 (0.54) | ENPP2PTGS2CA2 | |
| SCHEMBL2376239 | 0.79 | ENPP2 (0.72) | ENPP2PTGS2 | |
| SCHEMBL172035 | 0.78 | CA2 (0.64) | ENPP2PTGS2CA2DAO | |
| SCHEMBL14505689 | 0.76 | CA2 (0.64) | CA2 | |
| SCHEMBL10453282 | 0.76 | ENPP2 (0.50) | ENPP2PTGS2KCNJ1KCNH2DAO | |
| SCHEMBL4949390 | 0.76 | ENPP2 (0.50) | ENPP2PTGS2KCNJ1KCNH2CA2 | |
| SCHEMBL201356 | 0.76 | PSIP1 (0.65) | ENPP2PTGS2CA2 | |
| SCHEMBL22316942 | 0.76 | ENPP2 (0.50) | ENPP2PTGS2KCNJ1KCNH2CA2 | |
| SCHEMBL1751990 | 0.76 | ENPP2 (0.50) | ENPP2PTGS2KCNJ1KCNH2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113149971-B | 8- (indoletriazole) substituted coumarin compound and preparation method and application thereof | 港科鹏禾生物(苏州)有限公司 | 2022-12-16 | — | — | CN | disclosed |
| WO-2022237903-A1 | QUINAZOLINE COMPOUND, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海医药集团股份有限公司 | 2022-11-17 | — | — | WO | disclosed |
| EP-3452464-B1 | PYRAZOLE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USE THEREOF | HOFFMANN LA ROCHE (CH) | 2021-12-15 | — | — | EP | disclosed |
| CN-113149971-A | 8- (indoletriazole) substituted coumarin compound and preparation method and application thereof | 港科鹏禾生物(苏州)有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2012148548-A1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-01 | — | — | WO | disclosed |
| WO-2007047177-A1 | ACYL INDOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | ABBOTT LABORATORIES | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | FNTA, FNTB, SLC10A1 | ENPP2 1797/4885PTGS2 1634/4885KCNJ1 4169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.